In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Gilead gets filgotinib rights from Galapagos; deal amended following CRL for RA indication

Executive Summary

A few months after losing a major partner for the project, Galapagos NV has penned a new deal for its Phase II rheumatoid arthritis and Crohn's disease compound filgotinib, granting Gilead Sciences Inc. global rights to develop, manufacture, and sell the therapy. 

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register